SCHEMBL966356

SCHEMBL966356

COc1c(-c2nnc(Cc3ccccc3)o2)nc(N2CCN(c3cnccn3)CC2)c2cccnc12

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
GAA P10253 1/20 0.41
MAPK1 P28482 1/20 0.41
SMO Q99835 4/20 0.39
BCHE P06276 2/20 0.36
ACHE P22303 2/20 0.36
BACE1 P56817 2/20 0.36
RAB9A P51151 2/20 0.36
SCD O00767 2/20 0.35
CHRM4 P08173 1/20 0.35
TSHR P16473 2/20 0.34
NTSR1 P30989 1/20 0.34
NPC1 O15118 1/20 0.34
HPGD P15428 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
GPR55 Q9Y2T6 1/20 0.34
ALDH1A1 P00352 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL966726 0.87 MAPK1 (0.42) LMNAL3MBTL1GAAMAPK1SMO
SCHEMBL970618 0.87 GAA (0.41) LMNAL3MBTL1GAAMAPK1SMO
SCHEMBL967981 0.81 PRMT5 (0.37) RAB9ATSHRNPC1HPGDSMN1; SMN2
SCHEMBL967547 0.81 AURKA (0.39) LMNAGAARAB9ANPC1SMN1; SMN2
SCHEMBL965725 0.80 RAB9A (0.37) L3MBTL1RAB9ATSHRNPC1HPGD
SCHEMBL969722 0.78 RAB9A (0.45) LMNAL3MBTL1GAAMAPK1RAB9A
SCHEMBL967522 0.74 ACHE (0.42) LMNAL3MBTL1GAAMAPK1ACHE
SCHEMBL971586 0.73 GRIA1 (0.44) SMOACHEALDH1A1
SCHEMBL967751 0.71 RAB9A (0.48) MAPK1RAB9ANPC1HPGDSMN1; SMN2
SCHEMBL965866 0.70 KDM4E (0.39) LMNAL3MBTL1MAPK1SMORAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110003794-A1 Naphthyridine Integrase Inhibitors GSK LLC 2011-01-06 US disclosed
US-7812016-B2 Naphthyridine integrase inhibitors SMITHKLINE BEECHAM CORPORATION (US) 2010-10-12 US disclosed
EP-1622615-A4 NAPHTHYRIDINE INTEGRASE INHIBITORS SMITHKLINE BEECHAM CORP (US) 2009-02-18 EP disclosed
US-20070142365-A1 Naphthyridine integrase inhibitors GSK LLC 2007-06-21 US disclosed
EP-1622615-A2 NAPHTHYRIDINE INTEGRASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2006-02-08 EP disclosed
WO-2004101512-A2 NAPHTHYRIDINE INTEGRASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2004-11-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110003794-A1 Naphthyridine Integrase Inhibitors PCNA, SAMHD1, NTPCR LMNA 2352/4885L3MBTL1 2808/4885GAA 459/4885
US-20070142365-A1 Naphthyridine integrase inhibitors PCNA, SAMHD1, NTPCR LMNA 2352/4885L3MBTL1 2808/4885GAA 459/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.